IL6

Synonyms

CTL Differentiation Factor, Interleukin 6 (Interferon, Beta 2), HSF, B-cell stimulatory factor 2, Interferon beta-2, IL6, IFNB2, IL-6, Interleukin-6, Interleukin 6, Hybridoma Growth Factor, IFN-Beta-2, BSF-2, CDF, B-Cell Differentiation Factor, Interferon, Beta 2, Interleukin BSF-2, BSF2, HGF

KO Status

RenMab: In Vitro

Drug Information

Launched drugs: 5
Drugs in clinical trials: 18
Latest Research Phase: Approved

Drug Name

Code

Phase

Company

Indications

Clinical Trials

Luminol sodium

MP-1032

Approved

Selvim, Metrio

Coronavirus Disease 2019 (COVID-19), Immune System Diseases, Psoriasis

Thalidomide

NSC-66847, NSC-527179, K-17, VP-02

Approved

Celgene Corp

HIV Infections, Spondylitis, Ankylosing, Myelodysplastic Syndromes, Idiopathic Pulmonary Fibrosis, Multiple Myeloma, HIV Wasting Syndrome, Erythema Nodosum, Leprosy, Lepromatous, Carcinoma, Hepatocellular

Pomalidomide

IMID-4047, CDC-394, CC-4047, IMiD-1

Approved

Celgene Corp

Medulloblastoma, Bone Marrow Neoplasms, Lymphoma, B-Cell, Solid tumours, Scleroderma, Systemic, Lymphoma, Large B-Cell, Diffuse, Hodgkin Disease, Multiple Myeloma, Lung Diseases, Interstitial, Central Nervous System Neoplasms, Sarcoma, Prostatic Neoplasms, Lymphoma, Follicular, Primary Myelofibrosis, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Leukemia, Lymphocytic, Chronic, B-Cell, Sarcoma, Kaposi, Anemia, Sickle Cell

Siltuximab

cCLB-8, CNTO-328

Approved

Johnson & Johnson

Respiratory Tract Infections, Ovarian Neoplasms, Head and Neck Neoplasms, Pneumonia, Carcinoma, Renal Cell, Smoldering Multiple Myeloma, Myelodysplastic Syndromes, Pancreatic Neoplasms, Multiple Myeloma, Lung Diseases, Respiratory Distress Syndrome, Adult, Monoclonal Gammopathy of Undetermined Significance, Multicentric Castleman's Disease (MCD), Prostatic Neoplasms, Neoplasms, Plasma Cell, Colorectal Neoplasms, Castleman Disease, Lymphoma, Non-Hodgkin, Lung Neoplasms

Lenalidomide

IMID-5013, CDC-5013, CDC-501, CC-5013, IMiD-3, ENMD-0997

Approved

Celgene Corp

Leukemia, Myeloid, Lymphoma, B-Cell, Marginal Zone, Hematologic Diseases, Lymphoma, T-Cell, Peripheral, Solid tumours, Lymphoma, B-Cell, HIV Infections, Anemia, Paraproteinemias, Myelodysplastic Syndromes, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, Large B-Cell, Diffuse, Blood Protein Disorders, Smoldering Multiple Myeloma, Multiple Myeloma, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Prostatic Neoplasms, Reflex Sympathetic Dystrophy, Radiculopathy, Lymphoma, T-Cell, Lymphoma, Non-Hodgkin, Thrombocytopenia, Lymphoma, Waldenstrom Macroglobulinemia, Neoplasm Metastasis, Leukemia, Lymphocytic, Chronic, B-Cell, Melanoma, Carcinoma, Non-Small-Cell Lung, Crohn Disease, Complex Regional Pain Syndromes

Mycobacterium cell wall-DNA Complex (ProMetic Life Sciences)

EN-3348

NDA/BLA

Prometic Life Sciences

Neoplasm Recurrence, Local, Urinary Bladder Neoplasms, Carcinoma in Situ

Sirukumab

BA-003, CNTO-136

NDA/BLA

Glaxosmithkline Plc, Janssen Global Services Llc

Giant Cell Arteritis, Depressive Disorder, Major, Coronavirus Disease 2019 (COVID-19), Arthritis, Rheumatoid, Neoplasms, Lupus Erythematosus, Cutaneous, Lupus Nephritis, Polymyalgia Rheumatica, Lupus Erythematosus, Systemic, Asthma

Ensereptide

PXL-01

Phase 3 Clinical

Promore Pharma

Tissue Adhesions, Post-surgical adhesions, Cicatrix

Olokizumab

CDP-6038, Anti-IL6-UCB

Phase 3 Clinical

Ucb

Coronavirus Disease 2019 (COVID-19), Arthritis, Rheumatoid, Arthritis, Crohn Disease

Clazakizumab

ALD-518, ALD518-003, BMS-645429, BMS-945429

Phase 3 Clinical

Alder Biopharmaceuticals

Anemia, Graft vs Host Disease, Arthritis, Rheumatoid, Fatigue, Rejection of organ transplantation, Arthritis, Psoriatic, Inflammation, Cachexia, Carcinoma, Non-Small-Cell Lung, Crohn Disease, Stomatitis

References

Title

Authors

Source

SorLA in Interleukin-6 Signaling and Turnover

Larsen J.V., Petersen C.M.,

Mol. Cell. Biol. 37:0-0(2017)

Targeting Interleukin-6 Signaling in Clinic

Kang S., Tanaka T., Narazaki M., Kishimoto T.,

Immunity 50:1007-1023(2019)

Interleukin 6 is the principal cytolytic T lymphocyte differentiation factor for thymocytes in human leukocyte conditioned medium

Ming J.E., Cernetti C., Steinman R.M., Granelli-Piperno A.,

J. Mol. Cell. Immunol. 4:203-211(1989)

Marked cell-type-specific differences in glycosylation of human interleukin-6

May L.T., Shaw J.E., Khanna A.K., Zabriskie J.B., Sehgal P.B.,

Cytokine 3:204-211(1991)

Structure, stability and biological properties of a N-terminally truncated form of recombinant human interleukin-6 containing a single disulfide bond

Breton J., la Fiura A., Bertolero F., Orsini G., Valsasina B., Ziliotto R., de Filippis V., Polverino de Laureto P., Fontana A.,

Eur. J. Biochem. 227:573-581(1995)

Disulfide structures of human interleukin-6 are similar to those of human granulocyte colony stimulating factor

Clogston C.L., Boone T.C., Crandall B.C., Mendiaz E.A., Lu H.S.,

Arch. Biochem. Biophys. 272:144-151(1989)

Evidence for the importance of a positive charge and an alpha-helical structure of the C-terminus for biological activity of human IL-6

Luetticken C., Kruettgen A., Moeller C., Heinrich P.C., Rose-John S.,

FEBS Lett. 282:265-267(1991)

Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6

Steensberg A., van Hall G., Osada T., Sacchetti M., Saltin B., Klarlund Pedersen B.,

J. Physiol. (Lond.) 529:237-242(2000)

Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis

Nakahara H., Song J., Sugimoto M., Hagihara K., Kishimoto T., Yoshizaki K., Nishimoto N.,

Arthritis Rheum. 48:1521-1529(2003)

IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin

Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., Ganz T.,

J. Clin. Invest. 113:1271-1276(2004)

What's Next for the RenMice™ HiTS Platform?

Please stay tuned for the latest progress of our RenMice™ HiTS Platform. We are open to co-development programs to discover novel antibody therapeutics.
Please contact our team if you are interested in learning more about the HiTS Platform or would like to explore partnership.